Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.
Advertisement

Related Content

Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Omeros' Epic IPO Voyage Could be Delayed by a Former CFO's Lawsuit
Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too
Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too

Topics

Advertisement
UsernamePublicRestriction

Register

PS068711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel